AR071847A1 - Anticuerpos monoclonales modificadores de enfermedades cancerosas - Google Patents

Anticuerpos monoclonales modificadores de enfermedades cancerosas

Info

Publication number
AR071847A1
AR071847A1 ARP090101798A ARP090101798A AR071847A1 AR 071847 A1 AR071847 A1 AR 071847A1 AR P090101798 A ARP090101798 A AR P090101798A AR P090101798 A ARP090101798 A AR P090101798A AR 071847 A1 AR071847 A1 AR 071847A1
Authority
AR
Argentina
Prior art keywords
antibodies
cancer
monoclonal antibodies
cancer diseases
produce
Prior art date
Application number
ARP090101798A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR071847A1 publication Critical patent/AR071847A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Metodo para producir anticuerpos que modifican enfermedades cancerosas usando un paradigma de seleccion novedoso. Al segregar los anticuerpos anticancerosos usando citotoxicidad de celulas cancerosas como punto final, el proceso hace posible la produccion de anticuerpos anticancerosos para fines terapeuticos y diagnosticos. Los anticuerpos se pueden usar como ayuda para determinar el estadio y el diagnostico de c ncer, y se puede usar para tratar tumores primarios y met stasis tumorales. Los anticuerpos anticancerosos se pueden conjugar a toxinas, enzimas, compuestos radioactivos, y celulas hematogenas. Reivindicacion 1: El anticuerpo monoclonal aislado producido por el hibridoma depositado en el IDAC con el numero de acceso 200208-02.
ARP090101798A 2008-05-19 2009-05-19 Anticuerpos monoclonales modificadores de enfermedades cancerosas AR071847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5437208P 2008-05-19 2008-05-19

Publications (1)

Publication Number Publication Date
AR071847A1 true AR071847A1 (es) 2010-07-21

Family

ID=41339689

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101798A AR071847A1 (es) 2008-05-19 2009-05-19 Anticuerpos monoclonales modificadores de enfermedades cancerosas

Country Status (5)

Country Link
US (1) US20090304579A1 (es)
AR (1) AR071847A1 (es)
PE (1) PE20091973A1 (es)
TW (1) TW200948382A (es)
WO (1) WO2009140755A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455819A1 (en) * 2001-12-21 2004-09-15 Arius Research, Inc. Individualized anti-cancer antibodies

Also Published As

Publication number Publication date
PE20091973A1 (es) 2010-01-15
WO2009140755A1 (en) 2009-11-26
US20090304579A1 (en) 2009-12-10
TW200948382A (en) 2009-12-01

Similar Documents

Publication Publication Date Title
DK1718737T3 (da) Cancerøs sygdomsmodificerende antistoffer
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
AR063488A1 (es) Nuevos anticuerpos anti- cd38 para eltratamiento del cancer
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2004065422A3 (en) Cancerous disease modifying antibodies
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
WO2005012361A3 (en) Antibodies raised against colon carcinomas
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR070278A1 (es) Aislamiento y produccion de anticuerpos modificadores de enfermedades cancerosas (cdmab) y uso de los mismos
AR071308A1 (es) Anticuerpos monoclonales (producidos por el hibridoma idac 200208-03), que modifican enfermedades cancerosas
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
AR071846A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdmab)
ATE483028T1 (de) Antikörper, die krebserkrankungen modifizieren
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.

Legal Events

Date Code Title Description
FB Suspension of granting procedure